• Gilead agreed to acquire Ouro Medicines for USD 1.7 billion in cash at closing, plus up to USD 500 million in contingent milestone payments.
• Galapagos and Gilead are in advanced talks on a strategic collaboration covering the acquired Ouro assets, including the OM336 (gamgertamig) program.
• Under the contemplated terms, Galapagos would fund 50% of the upfront and 50% of any milestone payments to Ouro shareholders.
• Galapagos would take on substantially all of Ouro’s operating assets and retain its employees, while covering development costs through initiation of registrational studies.
• Gilead would hold worldwide commercialization rights outside Greater China and would pay Galapagos royalties of 20%-23% of net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231825OMX_____CNEWS_EN_GNW1001171777_en) on March 23, 2026, and is solely responsible for the information contained therein.